Here are the 10-K annual reports from ANI Pharmaceuticals, Inc. (ANIP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ANIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIP filings page.
ANI Pharmaceuticals files its annual report describing a diversified biopharma business built around Rare Disease, Generics, and Brands. The company highlights the September 2024 acquisition of Alimera Sciences, adding the retina drugs ILUVIEN and YUTIQ and expanding its international footprint.
In 2025, the FDA approved an expanded U.S. label for ILUVIEN to treat both diabetic macular edema and chronic non‑infectious uveitis, and cleared a prefilled syringe format for Cortrophin Gel to simplify use. ANI also strengthened its capital structure with a $325.0 million term loan, a $75.0 million revolver, and $316.25 million of convertible notes due 2029, largely used to fund the Alimera deal and refinance prior debt.
The Generics portfolio exceeds 120 products, and management targets 10–15 new launches per year while emphasizing niche, lower‑competition areas. As of June 30, 2025, non‑affiliate equity market value was about $1.3 billion, and as of February 20, 2026, there were 22,414,104 common shares outstanding.